NATF/SASAT 2008 Round Table

On September 28, 2008, NATF and the South Asian Society of Atherosclerosis and Thrombosis (SASAT), came together at the Brigham and Women's Hospital for an international summit. The discussion focused on current issues and regulatory considerations: Heparins at the Crossroad, Contaminants in Heparins, and Guidelines for Generic Low Molecular Weight Heparins.

PDF's for white papers on generic heparins below :

Current Issues Related to Heparins and the Contaminants in Heparins and Low Molecular Weight Heparins
Jawed Fareed, PhD

Differentiation of Low Molecular Weight Heparins
Russell D. Hull, MD

Differentiation of Low Molecular Weight Heparins
Jeanine M. Walenga, PhD

Manufacturing Process: The Influence on Heparins
Walter Jeske, PhD, and Erwin Coyne, PhD

Current EMEA Position on Biosimilars: European Perspective
Wolfram D. Raake, Munich, Germany

Overview of recommendations on biosimilar low-molecular-weight heparins obtained by the Scientific and Standardization Committee of the ISTH
Job Harenberg, Mannheim, Germany

Venous Thromboembolism: An Ounce of Prevention is Worth a Pound of Cure
Peter W. Marks, M.D., Ph.D. Section of Hematology Department of Medicine Yale University School of Medicine